Use of PD-1 vs PD-L1 Inhibitors in Patients With Cancer

This systematic review and meta-analysis of randomized clinical trials examines use of programmed cell death 1 (PD-1) vs programmed cell death–ligand 1 (PD-L1) treatment in patients with cancer.

Read the full article here

Related Articles